Significance of anemia in patients with CML at diagnosis and
during the treatment with imatinib outside the clinical trials:
CAMELIA registry experience

a 2015

Significance of anemia in patients with CML at diagnosis and during the treatment with imatinib outside the clinical trials: CAMELIA registry experience

FABER, Edgar; Jan MUŽÍK; Eva JANOUŠOVÁ; Tereza NEČASOVÁ; Pavel JINDRA et. al.

Basic information

Original name

Significance of anemia in patients with CML at diagnosis and during the treatment with imatinib outside the clinical trials: CAMELIA registry experience

Authors

Edition

20th Congress of European-Hematology-Association, 2015

Other information

Language

English

Type of outcome

Conference abstract

Field of Study

30200 3.2 Clinical medicine

Confidentiality degree

is not subject to a state or trade secret

References:

URL

Impact factor

Impact factor: 6.671

Organization unit

Institute of Biostatistics and Analyses

ISSN

Tags

International impact, Reviewed

Changed: 25/11/2015 13:04, RNDr. Tereza Nečasová

Cite

FABER, Edgar; Jan MUŽÍK; Eva JANOUŠOVÁ; Tereza NEČASOVÁ; Pavel JINDRA; Eduard CMUNT; Zuzana SNINSKÁ; Ludmila DEMITROVIČOVÁ; Eva MIKUŠKOVÁ; Juraj CHUDEJ; Imrich MARKULJAK; Stanislav PALÁŠTHY; Natália ŠTECOVÁ; Elena TÓTHOVÁ; Ladislav DUŠEK and Karel INDRÁK. Significance of anemia in patients with CML at diagnosis and during the treatment with imatinib outside the clinical trials: CAMELIA registry experience. In 20th Congress of European-Hematology-Association. 2015. ISSN 0390-6078.

@proceedings{1318605,
   author = {Faber, Edgar and Mužík, Jan and Janoušová, Eva and Nečasová, Tereza and Jindra, Pavel and Cmunt, Eduard and Sninská, Zuzana and Demitrovičová, Ludmila and Mikušková, Eva and Chudej, Juraj and Markuljak, Imrich and Palášthy, Stanislav and Štecová, Natália and Tóthová, Elena and Dušek, Ladislav and Indrák, Karel},
   booktitle = {20th Congress of European-Hematology-Association},
   language = {eng},
   title = {Significance of anemia in patients with CML at diagnosis and during the treatment with imatinib outside the clinical trials: CAMELIA registry experience},
   url = {http://learningcenter.ehaweb.org/eha/2015/20th/100327/edgar.faber.significance.of.anemia.in.patients.with.cml.at.diagnosis.and.html?f=m3},
   year = {2015}
}

TY  - CONF
ID  - 1318605
AU  - Faber, Edgar - Mužík, Jan - Janoušová, Eva - Nečasová, Tereza - Jindra, Pavel - Cmunt, Eduard - Sninská, Zuzana - Demitrovičová, Ludmila - Mikušková, Eva - Chudej, Juraj - Markuljak, Imrich - Palášthy, Stanislav - Štecová, Natália - Tóthová, Elena - Dušek, Ladislav - Indrák, Karel
PY  - 2015
TI  - Significance of anemia in patients with CML at diagnosis and during the treatment with imatinib outside the clinical trials: CAMELIA registry experience
UR  - http://learningcenter.ehaweb.org/eha/2015/20th/100327/edgar.faber.significance.of.anemia.in.patients.with.cml.at.diagnosis.and.html?f=m3
ER  -

FABER, Edgar; Jan MUŽÍK; Eva JANOUŠOVÁ; Tereza NEČASOVÁ; Pavel JINDRA; Eduard CMUNT; Zuzana SNINSKÁ; Ludmila DEMITROVIČOVÁ; Eva MIKUŠKOVÁ; Juraj CHUDEJ; Imrich MARKULJAK; Stanislav PALÁŠTHY; Natália ŠTECOVÁ; Elena TÓTHOVÁ; Ladislav DUŠEK and Karel INDRÁK. Significance of anemia in patients with CML at diagnosis and during the treatment with imatinib outside the clinical trials: CAMELIA registry experience. In \textit{20th Congress of European-Hematology-Association}. 2015. ISSN~0390-6078.

Přehled o publikaci